All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 23 October 20263 min read

Sagility (SAGILITY) Q2 FY27 Profit Growth Lags Behind Strong Revenue Jump

The healthcare BPM firm posted 22.5% revenue growth but saw profit margins compress, highlighting the cost pressures in a high-growth quarter.

By Vinayak Gandhi, CFA · Created 23 October 2026

Sagility's Q2 FY27 saw revenue surge 22.5% year-on-year, yet profit growth lagged at 13.3%. The gap points to margin pressure from wage hikes and acquisition costs, even as the company raises its full-year EBITDA guidance.

For Sagility, a business built on managing the complex revenue cycles of US healthcare payers, growth is rarely the question. The constant is demand from clients under cost pressure. The test each quarter is whether that top-line expansion translates into bottom-line gains. In Q2 FY27, revenue passed with a 22.5% year-on-year jump, but profit growth trailed at 13.3%, revealing a margin squeeze beneath the headline win.

Revenue reached ₹2,032 crore, up 3.5% sequentially. Profit after tax was ₹284 crore, a 31.1% jump from the previous quarter. That sharp sequential profit rise, however, is partly a base effect, as Investing.com notes Q1 carried a one-off minimum wage charge. The more telling comparison is year-on-year, where a 110-basis-point drop in net profit margin to 14.0% shows costs rising faster than sales.

Revenue (₹ Cr)

Profit (₹ Cr)

Net Margin (%)

MetricCurrentQ2 FY27PreviousQ1 FY27Same quarter LYQ2 FY26
Revenue (₹ Cr)
2032.1YoY +23%
1963.48
1658.5
Profit (₹ Cr)
284.21YoY +13%
216.81
250.83
Net Margin (%)
14.0YoY -7.3%
11.0
15.1

Why Profit Didn't Keep Pace

The growth was broad-based, driven by expansion with national payers and mid-market clients, according to the company's investor deck. Yet, the journey from revenue to profit was pinched. Management cited ongoing wage pressures in Karnataka and Telangana, with a full-quarter impact felt in Q2. Furthermore, amortisation of acquisition-related intangibles dragged on net profit. Stockwatch.live reported that Sagility's own adjusted PAT, which excludes such items, grew only 8.1% year-on-year, materially behind the revenue line.

The Outlook: Guidance Raised Amid Pressures

Despite the margin compression, operational efficiency provided a counterweight. Sagility reported its highest adjusted EBITDA margin in six quarters at 26.3%. This strength prompted management to raise its full-year FY27 adjusted EBITDA margin guidance to 25-26% from 24-25%, as noted by Investing.com. The revenue growth outlook remains unchanged at low double-digits in constant currency.

The company is also acting to bolster its slower-growing provider segment, which accounted for just 10.1% of Q2 revenue. Its acquisition of Chirok Health LLC, designed to fill a gap in mid-cycle revenue solutions, aims to accelerate growth there. For now, the story is one of strong top-line execution meeting persistent cost headwinds.

Key Points

  • Sagility's Q2 FY27 revenue grew 22.5% year-on-year to ₹2,032 crore, demonstrating robust demand from US healthcare clients.
  • Profit growth of 13.3% lagged revenue expansion, pulling the net profit margin down 110 basis points to 14.0%.
  • Margin pressure stemmed from full-quarter minimum wage impacts and acquisition-related amortisation costs.
  • Management raised its full-year adjusted EBITDA margin guidance to 25-26%, reflecting confidence in operational discipline.
  • The acquisition of Chirok Health is a strategic move to accelerate growth in the underpenetrated provider segment.

Hexa Perspective

Sagility's quarter confirms the durability of demand in its core payer business but also the fragility of margins in a people-intensive model facing wage inflation. The raised EBITDA guidance suggests management believes it can manage these pressures through operating leverage and cost discipline. The key watchpoint is whether the company can narrow the gap between revenue and profit growth as the one-time wage impact normalises and the Chirok acquisition starts contributing. For now, the stock's premium valuation of 20.2x P/E, against an industry average of 17.9x, prices in the growth but also demands that margin recovery follows.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Frequently asked questions

What were Sagility's Q2 FY27 results?
Sagility reported Q2 FY27 revenue of ₹2,032.1 crore, a 22.5% increase year-on-year. Profit after tax was ₹284.21 crore, up 13.3% from the same quarter last year. The company's net profit margin for the quarter was 14.0%.
Did Sagility's profit rise or fall in Q2 FY27?
Sagility's profit rose in Q2 FY27. Profit after tax increased by 13.3% year-on-year to ₹284.21 crore. Sequentially, profit jumped 31.1%, partly due to the absence of a one-off wage charge that impacted the previous quarter.
What is Sagility's revenue for Q2 FY27?
Sagility's revenue for the quarter ended September 2026 (Q2 FY27) was ₹2,032.1 crore. This represents a growth of 22.5% compared to the revenue of ₹1,658.5 crore reported in the same quarter of the previous fiscal year.
Why did Sagility's net profit margin decline in Q2 FY27?
Sagility's net profit margin fell 110 basis points to 14.0% due to cost pressures. According to company commentary and reports from Investing.com, full-quarter impacts from minimum wage hikes in Karnataka and Telangana, along with amortisation costs from recent acquisitions, compressed the bottom line despite strong revenue growth.
What drove Sagility's 22.5% revenue growth?
Sagility's revenue growth was driven by expansion within its existing national payer and mid-market clients. The company's investor deck highlighted broad-based momentum, with the payer segment representing 89.9% of quarterly revenue. It also won $40.2 million in annual contract value during the quarter.
What is Sagility's guidance for FY27 after Q2 results?
Following the Q2 results, Sagility raised its full-year adjusted EBITDA margin guidance to 25-26% from 24-25%. The company maintained its organic revenue growth outlook at low double-digits in constant currency, excluding acquisitions, as reported by Investing.com.
How did Sagility's stock react to the Q2 results?
According to Investing.com, Sagility's shares were up 2.21% following the Q2 FY27 results announcement. The market reaction was constructive, likely responding to the raised margin guidance and strong revenue growth, though the stock remained near the middle of its 52-week range.
What is the significance of Sagility's Chirok Health acquisition?
Sagility's acquisition of Chirok Health LLC is a strategic move to accelerate growth in its provider segment, which accounted for only 10.1% of Q2 revenue. Chirok adds clinical documentation improvement and coding capabilities, aiming to give Sagility a comprehensive end-to-end provider revenue cycle solution.
What are the key risks for Sagility's business?
Key risks for Sagility include client concentration, with the top three clients contributing 60.1% of trailing revenue, and regulatory changes affecting US healthcare programs like Medicare. Analyst reports also cite potential pricing pressure and AI-driven deflation of labour-intensive workflows as longer-term challenges.
Has institutional investor interest in Sagility changed?
Yes, institutional interest has grown. Data from Stockfin.ai shows Foreign Institutional Investor (FII) holdings increased from 5.6% in Q2 FY26 to 10.4% in Q2 FY27. Domestic Institutional Investor (DII) holdings also rose from 14.9% to 22.6% over the same period, indicating growing confidence.